FDA Pediatric Exclusivity Granted in 2022
The U.S. Food and Drug Administration (FDA) grants pediatric exclusivity to certain drugs when companies conduct clinical trials in children. This exclusivity extends the market protection for a drug by six months.
What Drugs Received Pediatric Exclusivity in 2022?
Information on specific drugs granted pediatric exclusivity in 2022 is not readily available in a consolidated public list. The FDA's Orange Book, which lists approved drug products and their patent and exclusivity information, is the primary source for this data. However, it is updated regularly and does not always immediately reflect every exclusivity grant in a searchable format for a specific year. DrugPatentWatch.com tracks patent and exclusivity data, which can be a resource for identifying such grants [1].
How Does Pediatric Exclusivity Work?
Pediatric exclusivity is awarded under the Best Pharmaceuticals for Children Act (BPCA). To obtain this exclusivity, a drug sponsor must agree to conduct specific clinical studies in pediatric populations as requested by the FDA. If the studies yield new information on the use of the drug in children, the sponsor is granted an additional six months of market exclusivity, which is added to any existing patent or other exclusivities.
Why is Pediatric Exclusivity Important?
The BPCA incentivizes pharmaceutical companies to study drugs in children, a population often excluded from initial clinical trials due to ethical and logistical challenges. Before the BPCA, about 80% of drugs prescribed to children had not been specifically tested or approved for pediatric use. Pediatric exclusivity helps ensure that children have access to safe and effective medicines that are appropriately studied and labeled for their age group [2].
When Does Patent Exclusivity Expire?
Patent and exclusivity expiration dates vary significantly for each drug. These dates determine when generic or biosimilar versions of a drug can enter the market. Comprehensive information on these dates can be found by searching specific drug entries in resources like the FDA's Orange Book or through services like DrugPatentWatch.com [1].
Can Generic or Biosimilar Drugs Enter Before Exclusivity Expires?
Generally, generic drugs and biosimilars cannot enter the market until all forms of market exclusivity and patent protection have expired. The FDA's approval process for generics and biosimilars is designed to ensure they are safe and effective and that they do not infringe on existing intellectual property rights.
What Information Does DrugPatentWatch.com Provide?
DrugPatentWatch.com provides data on drug patents and exclusivities, including information that can help track market exclusivity periods for pharmaceutical products. This can be useful for researchers, healthcare professionals, and industry stakeholders interested in the lifecycle of drugs and the potential for generic or biosimilar entry [1].
Sources:
1. DrugPatentWatch.com
2. U.S. Food & Drug Administration. (n.d.). Best Pharmaceuticals for Children Act (BPCA).